Fluid ChallengeNORA_FCNCT04934345
EFFECT OF VASOPRESSORS ON FLUID CHALLENGE PERSISTENCE AN OBSERVATIONAL STUDY IN PATIENTS UNDERGOING LAPAROTOMY.
An observational study of Fluid Challenge and Pharmakodynamic, run by Humanitas Clinical and Research Center at 1 site in Italy.
Trial summary
The hemodynamic effect of the fluid challenge administration (FC) depends on different variables related to the interplay between cardiac function and vascular tone response. In this context, the effect of adding a vasopressor to keep the arterial pressure between predefined ranges may impact on the persistence of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fluid Challenge, Pharmakodynamic, Norepinephrine
- What is being tested?
- Fluid challenge
- Type of treatment
- Injection or infusion
- How many people
- 50 participants
- Where
- 1 siteItaly
- Study dates
- 1 Sep 2021to 1 Sep 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Elective surgical patients scheduled for laparotomy >3h
Who may be able to join
- adult patients, scheduled for elective laparotomy (>3h predicted) and requiring a FC.
Who cannot join
- any recurrent cardiac arrhythmia;
- reduced left (ejection fraction < 30%) or right (systolic peak velocity of tricuspid annular motion < 0.17 m/s) ventricular systolic function.
- Once enrolled, the patient can be additionally excluded due to the occurrence of one of the following intraoperative conditions:
- significant bleeding (more than 500 ml in ½ hour)
- recurrent extrasystoles
- persistent low quality of the arterial signal affecting hemodynamic monitoring measurements
- intraoperative hemodynamic instability requiring the persistent use of vasopressors.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: EFFECT OF VASOPRESSORS ON FLUID CHALLENGE PERSISTENCE: AN OBSERVATIONAL STUDY IN PATIENTS UNDERGOING LAPAROTOMY.
The hemodynamic effect of the fluid challenge administration (FC) depends on different variables related to the interplay between cardiac function and vascular tone response.
In this context, the effect of adding a vasopressor to keep the arterial pressure between predefined ranges may impact on the persistence of stroke volume (SV) changes after FC administration. In fact, both the effect on arterial elastance and venous return may increase the persistence of SV increase, which is know to drop to baseline pre-FC values within fw minutes after FC administration.
This single-centre observational study, in elective patients scheduled for elective laparotomy, hypothesizes that intraoperative norepinephrine infusion would prolong the effect of FC administration.
Read the detailed description
The appropriate fluid management in the perioperative period is an important, and still partially unclear, chapter of clinical practice for anaesthesiologists. Increasing evidence suggests that intraoperative fluid therapy should be tailored to individual patient's physiology with the purpose of targeting fluid administration to specific stroke volume (SV) responses, or its surrogates. For this reason, small repeated and fast boluses challenging the cardiovascular system should be preferred to continuous and prolonged infusions.
The fluid challenge (FC) is defined as a small amount of fluid given in a short period of time to assess whether the preload reserve of the patient can increase SV with further administration of fluids. A number of studies performed in the operating room evaluated the hemodynamic effects of FC solely considering the effect before and after the infusion. Recently, Aya demonstrated that at least 4 ml kg-1 should be infused to effectively challenge the preload, additionally showing that the hemodynamic effect of the FC is dissipated within 10 minutes, in both responders and in non-responders.
The approach of Aya et al. considers the FC as a drug evoking a systemic response on flow (i.e. SV) and pressure variables [i.e. systolic arterial pressure (SAP)]. Accordingly, the pharmacodynamic effect is evaluated by considering the magnitude (i.e. the maximal changes from baseline obtained for a specific variable), the global effect [i.e. considering the area under the curve (AUC) obtained by plotting the changes overtime] and the persistence of the hemodynamic response after the end of FC administration. The infusion time of FC administration, which ranges in the literature between 5 and 30 minutes, may influence the magnitude of SV response and, in turn, the amount of patients defined as fluid responders . Since several intraoperative pathways of hemodynamic optimization are based on the response to repeated FCs, a prolonged infusion time may potentially affect fluid responsiveness and, in turn, wrongly drive intraoperative fluid management and eventually affect postoperative outcomes.
Since FC is a test embedding at least three variables (i.e. the amount of fluid; the time needed to complete the administration and the SV change threshold used to define a positive response), the role of a one single component on the final outcome can be addressed only by keeping fixed the others. Our group recently investigated the role of the infusion rate in a multicentre study (under revision at the timing of writing this protocol) and our research is now focused on the assessment of the role of the vascular tone in the persistence of the FC effect overtime. The previous study demonstrated that the rate of infusion impact on FC response, however another crucial issue is related to the persistence of the effect of the FC on the SV. In fact, the SV is determined by the interplay between cardiac function and arterial load. Diastolic filling depends on venous return, which is determined by the "stressed volume" and venous compliance. Systolic cardiac function depends on both cardiac factors and arterial load and is predominantly determined by arterial elastance (Ea) and resistance. For this reason, the effect of a vasopressor (i.e. the norepinephrine, the most widely used) may impact on the persistence of the increase of the SV after FC administration.
This single-centre observational study, in elective patients scheduled for elective laparotomy, hypothesizes that intraoperative norepinephrine infusion would prolong the effect of FC administration.
- Conditions
- Fluid Challenge, Pharmakodynamic, Norepinephrine, Surgery
- Being tested
- Fluid challenge
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fluid challengeDiagnostic test
The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
| Study group | Role | What they receive |
|---|---|---|
| FC administration | * All the patients receive crystalloids at 4 ml/kg/hour as maintenance fluid during surgery, according to standard practice.
* After the first episode of hypotension (MAP < 65 mmHg) the PPV is checked.
* PPV ≥ 13% - FC (4 ml/kg of crystalloids administered in 10')
* PPV < 13% - start norepinephrine (starting dose - 0.05 mcg/kg/min). In this group, the FC will be administered during an episode of intraoperative hypotension during NE infusion. Receives: Diagnostic Test: Fluid challenge |
What is being measured
The primary outcome is the main question the study is designed to answer.
Stroke volume persistance
Stroke volume estimation with respect to baseline values
Measured: evaluated within 10 minutes after fluid challenge infusion
Secondary outcomes (3)
Pharmakodynamic assesement of FC with and without NE
Area under the curve analysis
Measured: evaluated within 10 minutes after fluid challenge infusion
dmax
the maximal percentage difference of the SV observed from baseline
Measured: evaluated within 10 minutes after fluid challenge infusion
tmax
time when dmax maximal value was observed
Measured: evaluated within 10 minutes after fluid challenge infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2021
- Study start1 Sep 2021 (estimated)
- Primary completion1 Sep 2022 (estimated)
- Study completion1 Sep 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Fluid ChallengeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Humanitas Clinical and Research Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04934345
- Sponsor's protocol ID
- NORA_FC
- Acronym
- NORA_FC
- Status last verified
- Sep 2021
- First submitted
- 14 Jun 2021
- Last updated
- 9 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Publications
Aya HD, Ster IC, Fletcher N, Grounds RM, Rhodes A, Cecconi M. Pharmacodynamic Analysis of a Fluid Challenge. Crit Care Med. 2016 May;44(5):880-91. doi: 10.1097/CCM.0000000000001517.
PubMed 26683506Vincent JL. Fluid management in the critically ill. Kidney Int. 2019 Jul;96(1):52-57. doi: 10.1016/j.kint.2018.11.047. Epub 2019 Mar 4.
PubMed 30926137Monnet X, Teboul JL. Assessment of fluid responsiveness: recent advances. Curr Opin Crit Care. 2018 Jun;24(3):190-195. doi: 10.1097/MCC.0000000000000501.
PubMed 29634494
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EFFECT OF VASOPRESSORS ON FLUID CHALLENGE PERSISTENCE: AN OBSERVATIONAL STUDY IN PATIENTS UNDERGOING LAPAROTOMY.
- ClinicalTrials.gov ID
- NCT04934345
- Acronym / sponsor ID
- NORA_FC / NORA_FC
- Conditions
- Fluid Challenge, Pharmakodynamic, Norepinephrine, Surgery
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Humanitas Clinical and Research CenterUniversity, hospital or other
- Study start
- 1 Sep 2021 (estimated)
- Primary completion
- 1 Sep 2022 (estimated)
- Study completion
- 1 Sep 2022 (estimated)
- First posted
- 22 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The hemodynamic effect of the fluid challenge administration (FC) depends on different variables related to the interplay between cardiac function and vascular tone response.
In this context, the effect of adding a vasopressor to keep the arterial pressure between predefined ranges may impact on the persistence of stroke volume (SV) changes after FC administration. In fact, both the effect on arterial elastance and venous return may increase the persistence of SV increase, which is know to drop to baseline pre-FC values within fw minutes after FC administration.
This single-centre observational study, in elective patients scheduled for elective laparotomy, hypothesizes that intraoperative norepinephrine infusion would prolong the effect of FC administration.
Detailed description
The appropriate fluid management in the perioperative period is an important, and still partially unclear, chapter of clinical practice for anaesthesiologists. Increasing evidence suggests that intraoperative fluid therapy should be tailored to individual patient's physiology with the purpose of targeting fluid administration to specific stroke volume (SV) responses, or its surrogates. For this reason, small repeated and fast boluses challenging the cardiovascular system should be preferred to continuous and prolonged infusions.
The fluid challenge (FC) is defined as a small amount of fluid given in a short period of time to assess whether the preload reserve of the patient can increase SV with further administration of fluids. A number of studies performed in the operating room evaluated the hemodynamic effects of FC solely considering the effect before and after the infusion. Recently, Aya demonstrated that at least 4 ml kg-1 should be infused to effectively challenge the preload, additionally showing that the hemodynamic effect of the FC is dissipated within 10 minutes, in both responders and in non-responders.
The approach of Aya et al. considers the FC as a drug evoking a systemic response on flow (i.e. SV) and pressure variables [i.e. systolic arterial pressure (SAP)]. Accordingly, the pharmacodynamic effect is evaluated by considering the magnitude (i.e. the maximal changes from baseline obtained for a specific variable), the global effect [i.e. considering the area under the curve (AUC) obtained by plotting the changes overtime] and the persistence of the hemodynamic response after the end of FC administration. The infusion time of FC administration, which ranges in the literature between 5 and 30 minutes, may influence the magnitude of SV response and, in turn, the amount of patients defined as fluid responders . Since several intraoperative pathways of hemodynamic optimization are based on the response to repeated FCs, a prolonged infusion time may potentially affect fluid responsiveness and, in turn, wrongly drive intraoperative fluid management and eventually affect postoperative outcomes.
Since FC is a test embedding at least three variables (i.e. the amount of fluid; the time needed to complete the administration and the SV change threshold used to define a positive response), the role of a one single component on the final outcome can be addressed only by keeping fixed the others. Our group recently investigated the role of the infusion rate in a multicentre study (under revision at the timing of writing this protocol) and our research is now focused on the assessment of the role of the vascular tone in the persistence of the FC effect overtime. The previous study demonstrated that the rate of infusion impact on FC response, however another crucial issue is related to the persistence of the effect of the FC on the SV. In fact, the SV is determined by the interplay between cardiac function and arterial load. Diastolic filling depends on venous return, which is determined by the "stressed volume" and venous compliance. Systolic cardiac function depends on both cardiac factors and arterial load and is predominantly determined by arterial elastance (Ea) and resistance. For this reason, the effect of a vasopressor (i.e. the norepinephrine, the most widely used) may impact on the persistence of the increase of the SV after FC administration.
This single-centre observational study, in elective patients scheduled for elective laparotomy, hypothesizes that intraoperative norepinephrine infusion would prolong the effect of FC administration.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| FC administration | – | Diagnostic Test: Fluid challenge* All the patients receive crystalloids at 4 ml/kg/hour as maintenance fluid during surgery, according to standard practice. * After the first episode of hypotension (MAP < 65 mmHg) the PPV is checked. * PPV ≥ 13% - FC (4 ml/kg of crystalloids administered in 10') * PPV < 13% - start norepinephrine (starting dose - 0.05 mcg/kg/min). In this group, the FC will be administered during an episode of intraoperative hypotension during NE infusion. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Elective surgical patients scheduled for laparotomy >3h
Key inclusion criteria (1 listed)
- adult patients, scheduled for elective laparotomy (>3h predicted) and requiring a FC.
Key exclusion criteria (7 listed)
- any recurrent cardiac arrhythmia;
- reduced left (ejection fraction < 30%) or right (systolic peak velocity of tricuspid annular motion < 0.17 m/s) ventricular systolic function.
- Once enrolled, the patient can be additionally excluded due to the occurrence of one of the following intraoperative conditions:
- significant bleeding (more than 500 ml in ½ hour)
- recurrent extrasystoles
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fluid challengeThe fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes. | Diagnostic test | FC administration |
Primary outcome
Stroke volume persistance
Time frame: evaluated within 10 minutes after fluid challenge infusion
Stroke volume estimation with respect to baseline values
3 secondary outcomes
Pharmakodynamic assesement of FC with and without NE
Time frame: evaluated within 10 minutes after fluid challenge infusion
dmax
Time frame: evaluated within 10 minutes after fluid challenge infusion
tmax
Time frame: evaluated within 10 minutes after fluid challenge infusion
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2021.
- Background: PubMed 26683506Aya HD, Ster IC, Fletcher N, Grounds RM, Rhodes A, Cecconi M. Pharmacodynamic Analysis of a Fluid Challenge. Crit Care Med. 2016 May;44(5):880-91. doi: 10.1097/CCM.0000000000001517.
- Background: PubMed 30926137Vincent JL. Fluid management in the critically ill. Kidney Int. 2019 Jul;96(1):52-57. doi: 10.1016/j.kint.2018.11.047. Epub 2019 Mar 4.
- Background: PubMed 29634494Monnet X, Teboul JL. Assessment of fluid responsiveness: recent advances. Curr Opin Crit Care. 2018 Jun;24(3):190-195. doi: 10.1097/MCC.0000000000000501.
- Individual participant dataSharing planned: Undecided. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Related trials for Fluid Challenge
RecruitingObservational study
Role of End-Tidal CO2 During Passive Leg Raising to Predict Fluid Responsiveness in ICU
Circulatory Failure, Critical Illness
Not yet recruitingObservational study
Capillary Refill Time Variation to Predict Oxygen Comsumption Variation After FLuid Challenge (CARTOFL)
Critically Ill Patients, Circulatory Shock
Not yet recruitingObservational study
Fluid Responsiveness in Laparoscopic Surgery: End-Expiratory Occlusion Test Versus Mini-Fluid Challenge
Fluid Responsiveness, Laparoscopic Surgery
Not yet recruitingObservational study
Changes in Portal Vein Pulsatility Variability During a Tidal Volume Challenge Can Predict Fluid Tolerance
Venous Congestion
RecruitingObservational study
Respiratory Variation of Carotid Doppler Peak Velocity (CDPV) for Non-invasive Prediction of Fluid Responsiveness
Hemodynamic Instability
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fluid Challenge and Pharmakodynamic, run by Humanitas Clinical and Research Center at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stroke volume persistance (time frame: evaluated within 10 minutes after fluid challenge infusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04934345, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2021.